Financial Performance - Revenue for the three months ended December 31, 2019, was $381,899, compared to $1,054,805 for the same period in 2018, indicating a decrease in revenue [14]. - The net loss before income taxes for the three months ended December 31, 2019, was $(2,371,005), compared to $(6,468,720) for the same period in 2018, showing an improvement in loss [14]. - The company reported a comprehensive loss of $(2,629,496) for the three months ended December 31, 2019, compared to $(6,766,126) for the same period in 2018, reflecting a reduction in overall losses [14]. - For the nine months ended December 31, 2019, Biotricity Inc. reported a net loss of $6,492,391, compared to a net loss of $6,769,505 for the same period in 2018, indicating a decrease in losses of approximately 4.1% [20]. - The company incurred a net loss of $2,394,676 and $6,492,391 for the three and nine months ended December 31, 2019, respectively, with a loss per share of $0.066 and $0.181 [138]. - The Company incurred net losses of $2,394,676 and $6,492,391 for the three and nine months ended December 31, 2019, compared to net losses of $2,172,248 and $6,769,505 during the corresponding periods in 2018, resulting in a loss per share of $0.066 and $0.181 respectively [145]. Assets and Liabilities - As of December 31, 2019, total assets increased to $5.53 million from $490,660 as of March 31, 2019, reflecting a significant growth in current assets, particularly cash which rose to $4.35 million from $63,647 [10]. - Total current liabilities increased to $6.54 million as of December 31, 2019, from $2.27 million as of March 31, 2019, primarily due to an increase in accounts payable and accrued liabilities [10]. - The accumulated deficit as of December 31, 2019, was $(41,531,886), up from $(35,039,495) as of March 31, 2019, indicating a growing financial challenge [12]. - The total stockholders' deficiency as of December 31, 2019, was $(1,912,502), compared to $(1,777,681) as of March 31, 2019, indicating a decline in shareholder equity [12]. - As of December 31, 2019, the company has an accumulated deficit of $41,531,886 and a working capital deficiency of $1,355,227 [31]. Expenses - General and administrative expenses for the three months ended December 31, 2019, were $2,179,928, compared to $6,292,225 for the same period in 2018, indicating a decrease in operational costs [14]. - Research and development expenses for the three months ended December 31, 2019, were $447,639, compared to $879,661 for the same period in 2018, suggesting a reduction in R&D spending [14]. - Total operating expenses for the three and nine months ended December 31, 2019, were $2,627,567 and $7,171,886, compared to $2,262,384 and $6,905,143 for the same periods in 2018 [142]. - General and administrative expenses for the three and nine months ended December 31, 2019, were $2,179,928 and $6,292,225, respectively, reflecting increases due to higher borrowing costs and marketing expenses [143]. Financing Activities - The company issued 6,000 preferred shares, raising $6,000,000 during the period, which was a significant source of financing [20]. - The Company issued $6 million in preferred stock during the three months ended December 31, 2019, to support its operating plan [31]. - Net cash provided by financing activities was $9,464,675 for the nine months ended December 31, 2019, compared to $3,029,038 for the same period in 2018, primarily from the issuance of preferred shares and promissory notes [155]. - The Company issued convertible promissory notes totaling $1,368,978, which can be converted into common stock [50]. Revenue Growth - Gross revenues for the three months ended December 31, 2019, increased by 225% compared to the same period in the prior year, equating to 96% of the total gross revenues earned in the entire fiscal year ended March 31, 2019 [134]. - Technology fee revenues grew by over 500% for the nine months ended December 31, 2019, with approximately 65% of revenues being utilization-based annual recurring revenues (ARR) [135]. - Technology fees earned during the three-month and nine-month periods ended December 31, 2019, grew by 311.4% and 504.3%, respectively, from the prior year [141]. Strategic Focus - Biotricity is focused on developing technology for remote monitoring in preventative care, aiming to establish a realizable healthcare business model with a clear commercialization pathway [23]. - The Company plans to expand its sales efforts to 11 key states and aims to grow its sales force to enhance market penetration [113]. - The company expanded its sales force and geographic footprint to 11 US states, enhancing its market presence for the Bioflux® MCT device [136]. - The company is developing advanced ECG analysis software and the Bioflux® 2.0, with plans to apply for further FDA clearances within the next twelve months [116]. Stock and Options - The weighted average number of common shares outstanding increased to 36,176,520 for the three months ended December 31, 2019, from 35,826,398 for the same period in 2018 [14]. - The Company granted 3,591,000 options under the 2015 Equity Incentive Plan, with 3,390,503 options exercised [87]. - The maximum number of shares that may be issued under the 2016 Equity Incentive Plan is 3,750,000, with annual increases based on outstanding shares [90]. - The Company recorded stock-based compensation of $155,702 and $649,587 for the three and nine months ended December 31, 2019, respectively [95]. Cash Flow - Cash used in operating activities for the nine months ended December 31, 2019, was $4,909,896, an increase of approximately 20.9% compared to $4,063,375 in the same period of 2018 [20]. - The Company expects to require approximately $4 million to grow its sales team and order devices, with an additional $4 million anticipated for hiring a larger sales force and developing future technologies [151].

Financial Performance - Revenue for the three months ended September 30, 2019, was $345,906, a significant increase of 308.5% compared to $84,760 for the same period in 2018 [13]. - Net revenue for the six months ended September 30, 2019, reached $672,906, up 564.5% from $102,420 in the prior year [13]. - The net loss for the three months ended September 30, 2019, was $2,008,114, slightly improved from a loss of $2,176,740 in the same quarter of 2018 [13]. - For the six months ended September 30, 2019, the net loss was $4,097,714 compared to a net loss of $4,597,257 for the same period in 2018, indicating a reduction in losses by approximately 10.9% [20]. - Operating expenses for the three months ended September 30, 2019, totaled $2,239,804, slightly higher than $2,214,382 for the same period in 2018 [140]. Assets and Liabilities - As of September 30, 2019, total current assets increased to $661,113 from $457,660 as of March 31, 2019, representing a 44.4% growth [10]. - Total current liabilities surged to $5,788,844 as of September 30, 2019, compared to $2,268,341 as of March 31, 2019, marking a 154.5% increase [11]. - Total liabilities and stockholders' deficiency amounted to $1,057,761 as of September 30, 2019, compared to $490,660 as of March 31, 2019 [11]. - The accumulated deficit as of September 30, 2019, was $39,137,210, increasing from $35,039,495 as of March 31, 2019 [11]. - Cash flows from operating activities resulted in a net cash used of $2,790,973 for the six months ended September 30, 2019, compared to $2,670,638 for the same period in 2018, showing an increase in cash outflow of approximately 4.5% [20]. Shareholder Equity and Financing - The company raised $2,775,575 from the issuance of convertible debentures in the six months ended September 30, 2019, which was not present in the previous year [20]. - The company raised $3,746,575 in funding from a private equity fund, which committed to purchase up to $25 million in additional shares [31]. - The company issued shares for services amounting to $394,161 in the six months ended September 30, 2019, down from $898,025 in the same period of 2018, reflecting a decrease of about 56.2% [20]. - The company has a written commitment for an additional $5 million in debt financing from a private debt fund [31]. - The company anticipates requiring approximately $4 million to grow its sales team and order devices, with an additional $7 million needed to accelerate commercialization efforts [148]. Research and Development - Research and development expenses for the six months ended September 30, 2019, totaled $432,021, down from $487,930 in the prior year [13]. - Research and development expenses for the three months ended September 30, 2019, were $218,525, compared to $187,859 for the same period in 2018, indicating a 16% increase [142]. - A research partnership with the University of Calgary is established to explore the predictive value of ECG readings, funded partly by the National Research Council of Canada [112]. - The company plans to continue investing in capital expenditures and research and development to support higher sales volume and infrastructure [136]. Commercialization and Market Strategy - The company is focused on developing technology for remote monitoring in preventative care, aiming to establish a viable healthcare business model with a clear commercialization pathway [23]. - The company launched its first commercial sales program during the year ended March 31, 2019, utilizing an experienced in-house sales team [31]. - The company deployed over 900 remote patient monitoring devices as of September 30, 2019, almost tripling its fleet from the previous fiscal year-end [135]. - The company plans to expand its sales efforts to 11 key states and aims for further market penetration using an insourcing business model [110]. - The company intends to apply for further FDA clearances for several ancillary technologies during 2019 [110]. Stock and Options - The weighted average number of common shares outstanding increased to 35,659,133 for the three months ended September 30, 2019, compared to 32,819,848 in the same period of 2018 [13]. - The total shares issued as of September 30, 2019, were 36,091,753, an increase from 35,361,656 shares as of March 31, 2019, representing an increase of about 2.1% [17]. - The company granted 1,437,500 stock options during the year ended March 31, 2019, with a weighted average remaining contractual life of 2.76 to 9.51 years [90]. - The company recorded stock-based compensation of $154,996 and $493,885 for the three and six months ended September 30, 2019, respectively [93]. - The company issued 651,677 and 682,512 shares as compensation during the three and six months ended September 30, 2019, with the fair value determined at the market price at issuance [75]. Other Financial Information - The company reported an accumulated other comprehensive loss of $793,878 as of September 30, 2019, compared to $(754,963) as of March 31, 2019, reflecting a deterioration in comprehensive income [17]. - The company did not use any net cash in investing activities for the three-month periods ended September 30, 2019, or 2018 [153]. - There were no changes in the company's internal controls over financial reporting that materially affected its financial reporting during the three-month period ended September 30, 2019 [160].

Financial Performance - Total revenue for the three months ended June 30, 2019, was $327,000, a significant increase from $17,660 in the same period of 2018, representing a growth of approximately 1,752%[16] - Net revenue for the same period was $214,914, compared to $17,660 in 2018, indicating a growth of approximately 1,216%[16] - The net loss for the three months ended June 30, 2019, was $2,089,601, a decrease from a net loss of $2,420,516 in the same period of 2018, showing an improvement of about 13.6%[16] - The company reported a comprehensive loss of $2,112,187 for the three months ended June 30, 2019, compared to $2,523,165 in 2018, indicating a reduction of approximately 16.3%[16] - The net loss for the three months ended June 30, 2019, was $2,089,601, with a loss per share of $0.060[146] Assets and Liabilities - Total current assets increased to $600,698 as of June 30, 2019, from $457,660 as of March 31, 2019, reflecting a growth of about 31.2%[11] - Total liabilities rose to $4,312,330 as of June 30, 2019, compared to $2,268,341 as of March 31, 2019, marking an increase of approximately 90%[13] - The total stockholders' deficiency increased to $(3,265,396) as of June 30, 2019, from $(1,777,681) as of March 31, 2019, indicating a deterioration of approximately 83.5%[12] - As of June 30, 2019, the company had an accumulated deficit of $37,129,096 and a working capital deficiency of $3,491,691[33] Cash Flow - Cash on hand decreased to $47,750 as of June 30, 2019, from $63,647 as of March 31, 2019, representing a decline of about 25%[11] - Net cash used in operating activities was $1,328,375, compared to $1,209,549 in the prior period, reflecting an increase of about 9.8%[23] - Net cash provided by financing activities was $1,329,802 for the three months ended June 30, 2019, compared to $550,835 for the same period in 2018[158] Funding and Financing - The company raised $1,315,799 through the issuance of convertible promissory notes and short-term loans, contributing to a net cash provided by financing activities of $1,329,802, up from $550,835 in the previous period[23] - The company has raised $3,638,010 in funding from a private equity agreement, with a commitment to purchase up to $25 million in additional shares[33] - The company issued promissory notes and other short-term funding totaling $2,183,498 as of June 30, 2019, with an additional $1,514,115 raised subsequently[33] Operational Highlights - The company launched its first commercial sales program during the year ended March 31, 2019, utilizing an experienced in-house sales team[33] - The company is in the early stages of commercializing its first product while concurrently developing other proposed products[33] - The company aims to deliver innovative remote monitoring solutions in the multi-billion-dollar diagnostic mobile cardiac telemetry market[113] - The company is experiencing double-digit growth with an above 80% reorder rate, and plans to expand its sales efforts to 11 key states in the US[114] - The company aims to double the size of its sales force to enhance market penetration and address new markets[138] Research and Development - Research and development expenses for the three months ended June 30, 2019, were $213,496, down from $309,871 in 2018, reflecting a decrease of about 31%[16] - The company is developing additional ancillary technologies and plans to apply for further FDA clearances during 2019[114] - A research partnership with the University of Calgary is established to explore the predictive value of ECG readings for preventative healthcare applications, funded partly by the National Research Council of Canada[116] Stock and Equity - The weighted average number of common shares outstanding increased to 35,397,458 for the three months ended June 30, 2019, compared to 31,945,349 in 2018, an increase of approximately 10.5%[16] - The company had 31,101,975 shares of common stock issued and outstanding, an increase from 31,048,571 shares as of March 31, 2019[70] - The company raised gross proceeds of $3,718,010 through the issuance of 2,635,353 common shares during the year ended March 31, 2019[74] Accounting and Compliance - The company adopted ASC 842 for lease accounting, enhancing transparency by requiring the recording of right-of-use assets and corresponding lease liabilities[42] - The company has adopted new accounting standards related to leases and fair value measurements, which may impact financial reporting[127][130]

Company Overview - The company is a healthcare technology firm focused on developing software and hardware solutions for managing chronic health issues, with its first product being a wearable medical cardiac solution [275]. Revenue Recognition - The company adopted ASC 606 for revenue recognition on April 1, 2018, which requires revenue to be recognized when promised goods or services are transferred to customers [276]. - The Bioflux mobile cardiac telemetry device can be worn for up to 30 days, with revenues generated from device sales and technology fees, which are recognized when performance obligations are satisfied [277]. Financial Performance - For the fiscal year ended March 31, 2019, the Company sold approximately 300 Bioflux MCT devices, generating total income of $398,200 from device sales and technology fees [308]. - The net loss for the fiscal year ended March 31, 2019, was $8,592,065, a slight decrease from the net loss of $8,623,738 in the previous fiscal year [314]. - Total operating expenses for the fiscal year ended March 31, 2019, increased to $8,741,601 from $7,723,734 in the fiscal year ended March 31, 2018 [309]. - General and administrative expenses rose by $1,497,682 to $7,458,855 for the fiscal year ended March 31, 2019, primarily due to costs associated with establishing a sales force and increasing payroll [310]. - Research and development expenses decreased to $1,282,746 for the fiscal year ended March 31, 2019, down from $1,762,561 in the previous year [311]. - The Company has an accumulated deficit of $35,039,495 as of March 31, 2019 [319]. Cash Flow and Financing - Cash used in operating activities for the fiscal year ended March 31, 2019, was $5,220,847, an increase from $4,874,535 in the previous fiscal year [326]. - Net cash provided by financing activities was $4,556,544 for the fiscal year ended March 31, 2019, compared to $5,289,281 in the prior year, primarily due to the issuance of common shares and promissory notes [327]. - During the year ended March 31, 2019, the Company raised net proceeds of $3,638,010 through the issuance of 2,635,353 common shares [322]. - The company has entered into an arrangement with a private equity firm to raise up to $25 million in additional capital, subject to certain conditions [324]. - The company anticipates needing to seek additional debt or equity capital to respond to business opportunities and challenges, including ongoing operating expenses and intellectual property protection [324]. - The company believes its existing cash and anticipated near-term equity financings will be sufficient for the next twelve months from the filing date of the Annual Report [324]. - Future financing terms may be dilutive to common stockholders, and there is no assurance that additional capital can be raised on acceptable terms [324]. Research and Development - The company continues to pursue the development of its next generation MCT product and other new products [317]. - The company plans to further develop Bioflux and Biolife products to increase market penetration and expand its intellectual property platform [324]. - The company expects to require approximately $4 million to grow its sales team and order devices for revenue generation, with an additional $7 million needed to accelerate commercialization of Bioflux and Biolife products [324]. Inventory and Taxation - The company records inventory at the lower of cost or net realizable value, with write-downs charged to cost of revenue for obsolete or excess inventory [279]. - The company accounts for income taxes in accordance with ASC 740, recognizing deferred tax assets and liabilities based on enacted tax rates expected to apply in future periods [292]. Other Financial Information - The company has not entered into derivative instruments to offset foreign currency fluctuations, and its Canadian subsidiary operates in Canadian dollars while the parent company operates in U.S. dollars [284]. - As of March 31, 2019, there were no potentially dilutive shares outstanding, indicating a basic and diluted earnings per share calculation without dilution [281]. - The company has no off-balance sheet arrangements that could affect its financial condition or results of operations [329]. - Cash and derivative liabilities are classified as Level 1 and Level 2 financial instruments, respectively, with the carrying value of certain financial instruments approximating their fair values due to their short-term nature [289]. - The company is currently evaluating the effects of FASB ASU 2018-07 on its consolidated financial statements, which expands the scope of stock compensation to include nonemployee transactions [298].

[Part I – Financial Information](index=3&type=section&id=Part%20I%20%E2%80%93%20Financial%20Information) [Item 1 – Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201%20%E2%80%93%20Condensed%20Consolidated%20Financial%20Statements) The unaudited financial statements show an early-stage company with a growing net loss and stockholders' deficiency [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet reflects a significant cash reduction and a shift to a stockholders' deficiency of $850,731 Condensed Consolidated Balance Sheet Highlights (as of Dec 31, 2018 vs. Mar 31, 2018) | Metric | Dec 31, 2018 (Unaudited) | Mar 31, 2018 (Audited) | | :--- | :--- | :--- | | **Assets** | | | | Cash | $25,738 | $843,643 | | Total Current Assets | $440,098 | $896,426 | | **Total Assets** | **$473,098** | **$929,426** | | **Liabilities & Equity** | | | | Accounts payable and accrued liabilities | $1,305,677 | $756,179 | | **Total Liabilities** | **$1,323,829** | **$756,179** | | **Total stockholders' (deficiency) equity** | **($850,731)** | **$173,247** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) The company generated initial revenue but incurred a higher net loss of $6.77 million for the nine-month period Statement of Operations Summary (Nine Months Ended Dec 31) | Metric | 2018 (Unaudited) | 2017 (Unaudited) | | :--- | :--- | :--- | | Revenue | $220,060 | $0 | | Net Revenue | $135,638 | $0 | | Total Operating Expenses | $6,905,143 | $4,932,260 | | Net Loss | ($6,769,505) | ($5,832,264) | | Loss Per Share (Basic and Diluted) | ($0.206) | ($0.186) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations was $4.06 million, with financing activities providing $3.03 million in cash Cash Flow Summary (Nine Months Ended Dec 31, 2018 vs 2017) | Metric | 2018 (Unaudited) | 2017 (Unaudited) | | :--- | :--- | :--- | | Net cash used in operating activities | ($4,063,375) | ($3,236,926) | | Net cash provided by financing activities | $3,029,038 | $5,289,281 | | Net (decrease) increase in cash | ($1,034,337) | $2,052,355 | | Cash, end of period | $25,738 | $2,482,262 | [Notes to the Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's emerging growth status, significant deficits, and reliance on a $25 million equity facility - The company is an emerging growth entity in early commercialization, with an **accumulated deficit of $33,216,935** and a **working capital deficit of $883,731**[27](index=27&type=chunk) - Management believes its funding sources, including a **committed equity purchase facility of up to $25 million**, are sufficient to support operations for at least one year[27](index=27&type=chunk) - The company adopted ASU 2017-11, which resulted in the **reclassification of derivative liabilities to equity**, reducing the derivative liability balance to zero[65](index=65&type=chunk)[68](index=68&type=chunk) - Subsequent to the quarter end, the company sold **$400,000 in non-convertible notes** and issued **324,500 common shares** under its equity financing facility[114](index=114&type=chunk)[115](index=115&type=chunk) [Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202%20%E2%80%93%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the initial commercialization of its Bioflux device, operating results, and liquidity position [Company Overview](index=27&type=section&id=Company%20Overview) Biotricity focuses on remote patient monitoring, launching its Bioflux MCT technology and deploying 244 devices - The company is focused on biometric data monitoring solutions for diagnostic and post-diagnostic care, starting with the mobile cardiac telemetry (MCT) market[119](index=119&type=chunk) - Commercial sales of the Bioflux MCT technology began in April 2018, and by December 31, 2018, the company had placed **244 devices in the field**[120](index=120&type=chunk) [Results of Operations](index=32&type=section&id=Results%20of%20Operations) The company generated $220,060 in gross revenue and incurred a net loss of $6.8 million in its first nine months Revenue Breakdown (Nine Months Ended Dec 31, 2018) | Revenue Type | Amount | | :--- | :--- | | Device Sales Revenues | $86,800 | | Software Technology Service Fees | $133,260 | | **Total Gross Revenues** | **$220,060** | - Recurring software service fee revenues **grew over 200% in Q3 2018** compared to the immediately preceding quarter[156](index=156&type=chunk) Operating Expenses Comparison (Nine Months Ended Dec 31) | Expense Category | 2018 | 2017 | | :--- | :--- | :--- | | General & Administrative | $6,015,942 | $3,825,602 | | Research & Development | $889,201 | $1,106,658 | | **Total Operating Expenses** | **$6,905,143** | **$4,932,260** | [Liquidity and Capital Resources](index=33&type=section&id=Liquidity%20and%20Capital%20Resources) The company funds operations via a $25 million equity facility and believes it has sufficient liquidity for the next year - The company has an **accumulated deficit of $33,216,935** as of December 31, 2018, and has incurred recurring losses from operations[165](index=165&type=chunk) - A committed equity facility was established, allowing the company to raise up to **$25 million**, with **$3,039,480 in gross proceeds** raised during the nine months ended December 31, 2018[166](index=166&type=chunk) - Management estimates approximately **$4 million is required to grow the sales team** and believes existing cash and financing will be sufficient for the next twelve months[168](index=168&type=chunk)[169](index=169&type=chunk) [Item 3 – Quantitative and Qualitative Disclosures About Market Risk](index=36&type=section&id=Item%203%20%E2%80%93%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section is not required as the company qualifies as a smaller reporting company - Not required for a smaller reporting company[175](index=175&type=chunk) [Item 4 – Controls and Procedures](index=36&type=section&id=Item%204%20%E2%80%93%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective with no material changes in internal controls - The Company's Chief Executive Officer and Chief Financial Officer concluded that **disclosure controls and procedures were effective** as of the end of the period[178](index=178&type=chunk) - **No changes in internal controls** over financial reporting occurred during the quarter that materially affected, or are reasonably likely to materially affect, internal controls[179](index=179&type=chunk) [Part II – Other Information](index=37&type=section&id=Part%20II%20%E2%80%93%20Other%20Information) [Item 1 – Legal Proceedings](index=37&type=section&id=Item%201%20%E2%80%93%20Legal%20Proceedings) The company reported no legal proceedings during the period - None[182](index=182&type=chunk) [Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds](index=37&type=section&id=Item%202%20%E2%80%93%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - None[185](index=185&type=chunk) [Item 3 – Defaults Upon Senior Securities](index=37&type=section&id=Item%203%20%E2%80%93%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None[187](index=187&type=chunk) [Item 4 – Mine Safety Disclosures](index=37&type=section&id=Item%204%20%E2%80%93%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[189](index=189&type=chunk) [Item 5 – Other Information](index=37&type=section&id=Item%205%20%E2%80%93%20Other%20Information) The company reported no other information - None[191](index=191&type=chunk) [Item 6 – Exhibits](index=37&type=section&id=Item%206%20%E2%80%93%20Exhibits) This section lists exhibits filed with the report, including certifications and XBRL data files [Signatures](index=38&type=section&id=Signatures) The report was signed by the Chief Executive Officer and Chief Financial Officer on February 19, 2019 - The report was duly signed and authorized on **February 19, 2019**[194](index=194&type=chunk) - Signatories include **Waqaas Al-Siddiq (CEO)** and **John Ayanoglou (CFO)**[195](index=195&type=chunk)